Table of Contents
International Journal of Antibiotics
Volume 2014 (2014), Article ID 935842, 7 pages
http://dx.doi.org/10.1155/2014/935842
Research Article

The Occurrence of blaCTX-M, blaSHV, and blaTEM Genes in Extended-Spectrum β-Lactamase-Positive Strains of Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in Poland

1Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, 15a Waszyngtona Street, 15-269 Bialystok, Poland
2Department of Anaesthesiology and Intensive Therapy, Medical University of Bialystok, 37 Szpitalna Street, 15-274 Bialystok, Poland
3Department of Microbiological Diagnostics and Infectious Immunology, University Hospital of Bialystok, 15a Waszyngtona Street, 15-269 Bialystok, Poland
4Hospital Emergency Department with Intensive Care Subdivision, University Hospital of Bialystok, 24a M. Skłodowskiej-Curie Street, 15-276 Bialystok, Poland

Received 28 October 2013; Accepted 25 December 2013; Published 6 February 2014

Academic Editor: Cheol-In Kang

Copyright © 2014 Dominika Ojdana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Gaynes and J. R. Edwards, “Overview of nosocomial infections caused by gram-negative bacilli,” Clinical Infectious Diseases, vol. 41, no. 6, pp. 848–854, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. D. D. Pitout, “Multiresistant Enterobacteriaceae: new threat of an old problem,” Expert Review of Anti-Infective Therapy, vol. 6, no. 5, pp. 657–669, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Mathur, A. Kapil, B. Das, and B. Dhawan, “Prevalence of extended spectrum β lactamase producing Gram negative bacteria in a tertiary care hospital,” Indian Journal of Medical Research, vol. 115, pp. 153–157, 2002. View at Google Scholar · View at Scopus
  4. K. Bush and G. A. Jacoby, “Updated functional classification of β-lactamases,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 969–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Al-Jassera, “Extended-spectrum beta-lactamases (ESBLs): a global problem,” Kuwait Medical Journal, vol. 38, no. 3, pp. 171–185, 2006. View at Google Scholar
  6. A. A. Shah, F. Hasan, S. Ahmed, and A. Hameed, “Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β-lactamases,” Research in Microbiology, vol. 155, no. 6, pp. 409–421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. El salabi, T. R. Walsh, and C. Choichanic, “Extended spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria,” Critical Reviews in Microbiology, vol. 39, no. 2, pp. 113–122, 2012. View at Google Scholar
  8. K. Bush, “Extended-spectrum β-lactamases in North America, 1987–2006,” Clinical Microbiology and Infection, vol. 14, no. 1, pp. 134–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Cantón, A. Novais, A. Valverde et al., “Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe,” Clinical Microbiology and Infection, vol. 14, no. 1, pp. 144–153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Jarlier, M. H. Nicolas, G. Fournier, and A. Philippon, “Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns,” Reviews of Infectious Diseases, vol. 10, no. 4, pp. 867–878, 1988. View at Google Scholar · View at Scopus
  11. A. Sundsfjord, G. S. Simonsen, B. C. Haldorsen et al., “Genetic methods for detection of antimicrobial resistance,” Acta Pathologica et Immunologica Scandinavica, vol. 112, no. 11-12, pp. 815–837, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Bush, “Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections,” Critical Care, vol. 14, no. 3, pp. 224–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Govinden, C. Mocktar, P. Moodley, A. W. Sturm, and S. Y. Essack, “Geographical evolution of the CTX-M β-lactamase: an update,” African Journal of Biotechnology, vol. 6, no. 7, pp. 831–839, 2007. View at Google Scholar · View at Scopus
  14. D. M. Livermore, R. Canton, M. Gniadkowski et al., “CTX-M: changing the face of ESBLs in Europe,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, pp. 165–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. E. McGettigan, B. Hu, K. Andreacchio, I. Nachamkin, and P. H. Edelstein, “Prevalence of CTX-M β-lactamases in Philadelphia, Pennsylvania,” Journal of Clinical Microbiology, vol. 47, no. 9, pp. 2970–2974, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Vervoort, “Characterization of two new CTX-M-25-Group extended-spectrum beta-lactamase variants identified in Escherichiacoli isolates from Israel,” PLoS ONE, vol. 7, no. 9, Article ID e46329, 2012. View at Google Scholar
  17. K. Kasahara and P. H. Edelstein, “Novel Proteus mirabilis CTX-M,” http://www.uniprot.org/uniprot/D0ES28.
  18. I. Park and K. H. Kim, “Novel plasmid-encoded cefotaxime-hydrolyzing CTX-M-89 extended-spectrum beta-lactamase from clinical isolates of Enterobacter cloacae,” http://www.uniprot.org/uniprot/C5IUN2.
  19. T. Palzkill and D. Botstein, “Identification of amino acid substitutions that alter the substrate specificity of TEM-1 β-lactamase,” Journal of Bacteriology, vol. 174, no. 16, pp. 5237–5243, 1992. View at Google Scholar · View at Scopus
  20. L. G. Mesa, A. R. Morí, L. N. Becerra et al., “Phenotypic and molecular identification of extended-spectrum β-lactamase (ESBL) TEM and SHV produced by clinical isolates Escherichia coli and Klebsiella spp. in hospitals,” Revista Cubana de Medicina Tropical, vol. 59, no. 1, pp. 52–58, 2007. View at Google Scholar · View at Scopus
  21. A. Baraniak, J. Fiett, A. Mrówka, J. Walory, W. Hryniewicz, and M. Gniadkowski, “Evolution of TEM-type extended-spectrum β-lactamases in clinical Enterobacteriaceae strains in Poland,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 5, pp. 1872–1880, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. T. M. Coque, F. Baquero, and R. Canton, “Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe,” Euro Surveillance, vol. 13, no. 47, pp. 1–11, 2008. View at Google Scholar · View at Scopus
  23. P. Sacha, D. Ojdana, P. Wieczorek et al., “Profiles of phenotype resistance to antibiotic other than β-lactams in Klebsiella pneumoniae ESBLs-producers, carrying blaSHV genes,” Folia Histochemica et Cytobiologica, vol. 48, no. 4, pp. 663–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. H. Jones, M. Tuckman, D. Keeney, A. Ruzin, and P. A. Bradford, “Characterization and sequence analysis of extended-spectrum-β-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 465–475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Nijssen, A. Florijn, M. J. M. Bonten, F. J. Schmitz, J. Verhoef, and A. C. Fluit, “Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates,” International Journal of Antimicrobial Agents, vol. 24, no. 6, pp. 585–591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Schultsz and S. Geerlings, “Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy,” Drugs, vol. 72, no. 1, pp. 1–16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Lynch, N. M. Clark, and G. G. Zhanerl, “Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum beta-lactamases and carbapenemases),” Expert Opinion on Pharmacotherapy, vol. 14, no. 2, pp. 199–210, 2013. View at Google Scholar
  28. H. Giamarellou and G. Poulakou, “Multidrug-resistant gram-negative infections: what are the treatment options?” Drugs, vol. 69, no. 14, pp. 1879–1901, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Giamarellou, “Multidrug-resistant Gram-negative bacteria: how to treat and for how long,” International Journal of Antimicrobial Agents, vol. 36, no. 2, pp. S50–S54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. N. H. Chan-Tompkins, “Multidrug-resistant gram-negative infections bringing back the old,” Critical Care Nursing Quarterly, vol. 34, no. 2, pp. 87–100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. D. L. Paterson, “Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs),” Clinical Microbiology and Infection, vol. 6, no. 9, pp. 460–463, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Babypadmini and B. Appalaraju, “Extended spectrum β-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae: prevalence and susceptibility pattern in a tertiary care hospital,” Indian Journal of Medical Microbiology, vol. 22, no. 3, pp. 172–174, 2004. View at Google Scholar · View at Scopus
  33. S. Jaiswal, N. Kastury, A. K. Kapoor, A. R. Tiwari, and A. Bhargava, “A study of antibiotic sensitivity pattern in gram-negative urinary isolates with special reference to extended spectrum beta lactamase producers,” Biomedicine, vol. 27, no. 4, pp. 162–167, 2007. View at Google Scholar · View at Scopus
  34. G. M. Rossolini, E. Mantengoli, J.-D. Docquier, R. A. Musmanno, and G. Coratza, “Epidemiology of infections caused by multiresistant Gram-negatives: ESBLs, MBLs, panresistant strains,” New Microbiologica, vol. 30, no. 3, pp. 332–339, 2007. View at Google Scholar · View at Scopus
  35. A. M. Nicasio, J. L. Kuti, and D. P. Nicolau, “The current state of multidrug-resistant gram-negative bacilli in North America: insights from the society of infectious diseases pharmacists,” Pharmacotherapy, vol. 28, no. 2, pp. 235–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Bush, “Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae,” Current Opinion in Microbiology, vol. 13, no. 5, pp. 558–564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Sacha, P. Wieczorek, D. Ojdana et al., “Antibiotic susceptibility and the presence of presence of blaIMP and blaVIM genes among Pseudomonas aeruginosa strains resistant or susceptible to imipenem,” Progress in Health Sciences, vol. 2, no. 1, pp. 12–18, 2012. View at Google Scholar
  38. M. A. Leverstein-van Hall, A. T. A. Box, H. E. M. Blok, A. Paauw, A. C. Fluit, and J. Verhoef, “Evidence of extensive interspecies transfer of integron-mediated antimicrobial resistance genes among multidrug-resistant Enterobacteriaceae in a clinical setting,” Journal of Infectious Diseases, vol. 186, no. 1, pp. 49–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Carattoli, “Resistance plasmid families in Enterobacteriaceae,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 6, pp. 2227–2238, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Colodner, “Extended-spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists,” The American Journal of Infection Control, vol. 33, no. 2, pp. 104–107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Dierżanowska, W. Kamińska, K. Semczuk et al., “Carriage of genes for various extended spectrum beta-lactamases: a novel resistance strategy of Klebsiella pneumoniae in Poland,” International Journal of Antimicrobial Agents, vol. 35, no. 4, pp. 392–395, 2010. View at Google Scholar